Sumitomo Mitsui DS Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Sumitomo Mitsui DS Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,132	Closed	-$307K	–	772
2021 Q1	$307K	Buy	4,132 +43	+1%	+$3.97K	0.01%	699
2020 Q4	$697K	Sell	4,089 -43	-1%	-$6.37K	0.02%	552
2020 Q3	$580K	Buy	4,132 +12	+0.3%	+$1.82K	0.02%	545
2020 Q2	$660K	Hold	4,120	–	–	0.02%	507
2020 Q1	$403K	Buy	4,120 +27	+0.7%	+$3.09K	0.02%	542
2019 Q4	$528K	Buy	4,093 +669	+20%	+$67.5K	0.02%	585
2019 Q3	$257K	Buy	+3,424	New	+$404K	0.01%	669

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management's SRPT Position: Q2 2021 in Review

Sumitomo Mitsui DS Asset Management sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 4,132 shares — an estimated $307K sold.

Sumitomo Mitsui DS Asset Management first reported a position in SRPT in Q3 2019 and held it in 7 quarters. The position peaked at $697K in Q4 2020. 331 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

Sumitomo Mitsui DS Asset Management reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
Sumitomo Mitsui DS Asset Management sold 4,132 Sarepta Therapeutics shares in Q2 2021, an estimated $307K.
Sumitomo Mitsui DS Asset Management first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 7 quarters.
Sumitomo Mitsui DS Asset Management's Sarepta Therapeutics position peaked at $697K in Q4 2020.
331 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Sumitomo Mitsui DS Asset Management's 13F filing for Q2 2021, filed 19 Jul 2021.